Carglumic acid is an orphan drug that is used for treating patients suffering from hyperammonemia, a urea cycle disorder that is caused due to the lack of a certain enzyme in the liver. This also implies deficiency of N-acetylglutamate (NAG) synthase. Carglumic acid helps in detoxification and removal of ammonia from blood cells.
Carglumic acid is on the verge of becoming an indispensable tool for managing life-threating metabolic disorders that affect the urea cycle. Carglumic acid is also being used in enhancing ammonia detoxification in patients with organic acidurias. Recently, carglumic acid has also shown potential for anti-tumor activity in breast cancer. Carglumic acid activates caspase 3 which helps in promoting cell apoptosis and also suppress tumor growth. Meanwhile, new formulations are also being developed by leading pharmaceutical companies to effectively treat urea cycle disorders and also to strengthen their product portfolio. In order to prevent brain damage in children, researchers have also combined metabolomics analysis of carglumic acid with genome sequencing.The report also offers a detailed profile of some of the leading players in the global market for carglumic acid such as Dipharma Francis S.r.l, Recordati S.p.A, and Civentichem, LLC.
Request A Sample-
Global Market for Carglumic Acid to Witness Robust Growth during the Forecast Period 2017-2026
According to a study by Transparency Market Research (TMR), the global market for carglumic acid is likely to witness strong growth. The market is projected to register 7.5% CAGR during the forecast period 2017-2026. It is also estimated to bring in US$ 187.0 million revenue by the end of 2026.